Diagnosis and treatment of lung infection with nontuberculous mycobacteria

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 3, 2009, Pages 201-208

  Arend, Sandra M ^a   Van Soolingen, Dick ^b   Ottenhoff, Tom Hm ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Lung infection; Nontuberculous mycobacteria; Review

Indexed keywords

AZITHROMYCIN; BCG VACCINE; CLARITHROMYCIN; EARLY SECRETORY ANTIGENIC TARGET 6; ETANERCEPT; ETHAMBUTOL; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; LINEZOLID; MACROLIDE; RIFAMPICIN; STREPTOMYCIN; THALIDOMIDE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CYSTIC FIBROSIS; DRUG CHOICE; FUNNEL CHEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMOTILE CILIA SYNDROME; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFECTION PREVENTION; LUNG RESECTION; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM SZULGAI; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; NONTUBERCULOUS MYCOBACTERIUM; RADIOLOGY; REVIEW; RISK FACTOR; SCOLIOSIS; SERODIAGNOSIS; TUBERCULOSIS; MICROBIOLOGY; MYCOBACTERIUM; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 67649236784     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283292679     Document Type: Review

References (86)

1. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest 2008; 133:243-251.
2. Johnson MM, Waller EA, Leventhal JP. Nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med 2008; 14:203-210.
3. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
4. Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest 2006; 129:1653-1672.
5. Bruijnesteijn van Coppenraet LE, de Haas PE, Lindeboom JA, et al. Lymphadenitis in children is caused by Mycobacterium avium hominissuis and not related to 'bird tuberculosis'. Eur J Clin Microbiol Infect Dis 2008; 27:293-299.
6. Mijs W, de Haas P, Rossau R, et al. Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium. Int J Syst Evol Microbiol 2002; 52:1505-1518.
7. Salvana EM, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 2007; 55:484-487.
8. van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14:385-389.
9. Emmanuel FX, Seagar AL, Doig C, et al. Human and animal infections with Mycobacterium microti, Scotland. Emerg Infect Dis 2007; 13:1924-1927.
10. Pandian TK, Deziel PJ, Otley CC, et al. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 2008; 10:358-363.
11. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother 2007; 8:2965-2978.
12. Portaels F, Meyers WM, Ablordey A, et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008; 2:e178.
13. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13:1653-1660.
14. Buijtels PC, Petit PL, Verbrugh HA, et al. Isolation of nontuberculous mycobacteria in Zambia: eight case reports. J Clin Microbiol 2005; 43:6020-6026.
15. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007; 176:306-313.
16. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84:291-302.
17. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44:714-720.
18. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 20:443-449.
19. Maimon N, Brunton J, Chan AK, Marras TK. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 2007; 62:739-740.
20. Marie I, Heliot P, Roussel F, et al. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford) 2005; 44:1201-1202.
21. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265.
22. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving antitumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738-1740.
23. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford) 2005; 44:1205-1206.
24. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-1772.
25. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007; 137:620-622.
26. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002- 2003. MMWR Morb Mortal Wkly Rep 2004; 53:683-686.
27. Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med 2003; 61:111-119.
28. Phillips DR, Krishnan H, Watson J. First UK report of successful treatment of Mycobacterium simiae and immune reconstitution inflammatory syndrome in an HIV-seropositive patient. Sex Transm Infect 2008; 84:271-272.
29. Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008; 68:191-208.
30. Arend SM, Leyten EM, Franken WP, et al. A patient with de novo tuberculosis during antitumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45:1470-1475.
31. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005; 9:1057-1058.
32. Garcia VC, Rodriguez FS, Martinez LJ, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:756-759.
33. van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004; 4:739-749.
34. Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infections. Chest 2006; 130:995-1002.
35. Chan ED, Kaminska AM, Gill W, et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 2007; 39:690-696.
36. Tanaka G, Shojima J, Matsushita I, et al. Pulmonary Mycobacterium avium complex infection: association with NRAMP1 polymorphisms. Eur Respir J 2007; 30:90-96.
37. Ryu YJ, Kim EJ, Lee SH, et al. Impaired expression of Toll-like receptor 2 in nontuberculous mycobacterial lung disease. Eur Respir J 2007; 30:736-742.
38. Piersimoni C, Scarparo C. Pulmonary infections associated with nontuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis 2008; 8:323-334.
39. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991; 143:1381-1385.
40. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000; 30:572-575.
41. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364:2113-2121.
42. Wallace RJ, Glassroth J, Griffith DE. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25.
43. Bodle EE, Cunningham JA, la-Latta P, et al. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008; 14:390-396.
44. Hollings NP, Wells AU, Wilson R, Hansell DM. Comparative appearances of nontuberculous mycobacteria species: a CT study. Eur Radiol 2002; 12:2211-2217.
45. Jeong YJ, Lee KS, Koh WJ, et al. Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology 2004; 231:880-886.
46. Cattamanchi A, Nahid P, Marras TK, et al. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 2008; 133:875-880.
47. Chung MJ, Lee KS, Koh WJ, et al. Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between Mycobacterium avium-intracellulare complex and Mycobacterium abscessus infection. J Korean Med Sci 2005; 20:777-783.
48. Chung MJ, Lee KS, Koh WJ, et al. Drug-sensitive tuberculosis, multidrugresistant tuberculosis, and nontuberculous mycobacterial pulmonary disease in nonAIDS adults: comparisons of thin-section CT findings. Eur Radiol 2006; 16:1934-1941.
49. Fine PE, Floyd S, Stanford JL, et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect 2001; 126:379-387.
50. Lindeboom JA, Kuijper EJ, Prins JM, et al. Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2006; 43:1547-1551.
51. Arend SM, Franken WP, Aggerbeck H, et al. Double-blind randomized phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis (Edinb) 2008; 88:249-261.
52. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis. Part I: Latent tuberculosis. Expert Rev Mol Diagn 2006; 6:413-422.
53. Pai M, Dheda K, Cunningham J, et al. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7:428-438.
54. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection - areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340-354.
55. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection - an update. Ann Intern Med 2008; 149:177-184.
56. Janssens JP. Interferon-gamma release assay tests to rule out active tuberculosis. Eur Respir J 2007; 30:183-184.
57. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 2007; 44:69-73.
58. Arend SM, de Haas P, Leyten E, et al. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis 2005; 191:1301-1310.
59. Arend SM, van Meijgaarden KE, de Boer K, et al. Tuberculin skin testing and in vitroT cell responses toESAT-6 and culture filtrate protein 10after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002; 186:1797-1807.
60. Vordermeier HM, Brown J, Cockle PJ, et al. Assessment of cross-reactivity between Mycobacterium bovis and M. kansasii ESAT-6 and CFP-10 at the Tcell epitope level. Clin Vaccine Immunol 2007; 14:1203-1209.
61. Kobashi Y, Obase Y, Fukuda M, et al. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 2006; 43:1540-1546.
62. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J 2005; 26:339-350.
63. Kobashi Y, Yoshida K, Miyashita N, et al. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 2006; 12:195-202.
64. National Committee for Clinical Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardiae and other aerobic actinomycetes. Approved standard M24-A. NCCLS: Wayne, PA, USA; 2003.
65. van Klingeren B, Dessens-Kroon M, van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007; 45: 2662-2668.
66. Ruiz-Aragon J, Garcia-Agudo L, Flores S, et al. Susceptibility to antimicrobial agents of rapidly growing mycobacteria. Rev Esp Quimioter 2007; 20:429-432.
67. Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007; 20:198-203.
68. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007; 74:394-400.
69. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101:130-138.
70. Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173:1283-1289.
71. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174:928-934.
72. de Souza MV. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr Opin Pulm Med 2006; 12:167-171.
73. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006; 12:4047-4070.
74. Mitchell JD, Bishop A, Cafaro A, et al. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008; 85:1887-1892.
75. Koh WJ, Kim YH, Kwon OJ, et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci 2008; 23:397-401.
76. Holland SM. Cytokine therapy of mycobacterial infections. Adv Intern Med 2000; 45:431-452.
77. Ward CM, Jyonouchi H, Kotenko SV, et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur J Pediatr 2007; 166:981-985.
78. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994; 330:1348-1355.
79. Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47-59.
80. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1:384-397.
81. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41:201-208.
82. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-1104.
83. Geluk A, Klein MR, Franken KL, et al. Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection. Infect Immun 2005; 73:5636-5644.
84. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3:656-662.
85. Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 2005; 73:2190-2196.
86. Reece ST, Kaufmann SH. Rational design of vaccines against tuberculosis directed by basic immunology. Int J Med Microbiol 2008; 298:143-150.